InVivo Therapeutics (NVIV.OB) says it raised $16.1M from the exercise of warrants from 2010...


InVivo Therapeutics (NVIV.OB) says it raised $16.1M from the exercise of warrants from 2010 until their expiration this month and notes that when combined with a recent warrant exchange offer, the effect has been the elimination of a $24.6M warrant liability from the books (in other words: the company no longer has negative stockholders equity). The takeaway: "the last major impediment to up-listing to a national securities exchange has been removed," CEO Frank Reynolds says. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs